In this issue, Eichhorst and colleagues show in a large randomized phase 3 clinical trial that combination therapy using fludarabine and cyclophosphamide is superior to fludarabine alone for younger previously untreated CLL patients. In addition, they found a reduced level of clinical responses when imaging was considered as part of restaging compared with responses defined by recommended NCI standards.
|Original language||English (US)|
|Number of pages||1|
|State||Published - Feb 1 2006|
ASJC Scopus subject areas
- Cell Biology